Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Clinical trial NCT04139434 · COMPLETED
Trial details
- NCT number
- NCT04139434
- Sponsor
- Newave Pharmaceutical Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-06
- Primary completion
- 2025-12-19
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.